Navigation Links
AIDS Foundation Lauds Brazil for Negotiating Price Cut on Abbott's Kaletra

AIDS Healthcare Foundation (AHF), the US' largest HIV/AIDS healthcare, prevention and education provider, which operates free AIDS treatment clinics in the US, Africa, Latin America/Caribbean and Asia, today lauded the government of Brazil for successfully negotiating a price cut of 30% on Abbott Laboratories' lifesaving medication, Kaletra (its two drug AIDS drug combination including lopinavir and ritonavir).

According to Bloomberg News Service, Brazil has pressed for discount prices on AIDS drugs to limit the cost of its program providing free treatment to all 200,000 people infected with AIDS and the HIV virus. The agreement extends to Brazil the same price structure Abbott has offered 44 other countries considered low and low-middle income, and it replaces a deal signed in 2005 when it lowered the price of the previous version of Kaletra by 46 percent in Brazil after the government threatened to break its patent.

"We commend the Government of Brazil for successfully negotiating this additional and significant price cut on a more patient-friendly version of Abbott's AIDS combination treatment, Kaletra," said Michael Weinstein, AIDS Healthcare Foundation's President. "However, this 30% price reduction on top of Brazil's previously-negotiated 46% price discount underscores to anyone who understands the most basic of mathematics just how random and arbitrary AIDS drug pricing by multi-national drug companies can be. Abbott has been the pharmaceutical industry's poster child for bad behavior of late -- they've blacklisted Thailand from any of its new drugs, sued the advocacy group, ACT Up Paris, and run rampant over a number of other recent drug access issues put forth by a number of advocacy groups. A 76% reduction on this lifesaving combination may seem significant for Brazil, but we still believe Abbott -- like most pharmaceutical companies -- can do far, far more to improve pricing and access to their lifesaving AIDS drugs around t he world." According to Bloomberg, "Kaletra is a protease inhibitor that blocks an enzyme involved in the virus's replication, slowing its progression to AIDS.

It's often used in combination with other drugs. It's the second most-used drug on Brazil's AIDS cocktail. About 31,000 adults and 1,200 children ingest it daily in Brazil."


Related medicine news :

1. Woodruff Foundation Grant To Support Doctorate Of Nursing Practice Program
2. Kalam To Lay Foundation Of Vellore Research Center
3. Nippon Foundation To Help Leprosy Patients
4. Parents Launch SV40 Cancer Foundation In Memory of Son
5. Cancer Aid And Research Foundation: Offering Endless Hope To Cancer Patients
6. PM Launches Healthcare Foundation For India
7. Prime Minister Manmohan Singh, Flags Off Public Health Foundation of India
8. Gates Foundation to donate USD 104 million to TB Alliance
9. MoU for HIV/AIDS Signed by Nigeria and Clinton Foundation
10. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
11. Gates Foundation Adopts Fight against Encephalitis
Post Your Comments:

(Date:11/24/2015)... , ... November 24, 2015 , ... In an ... restrictions and variables that determine which patients are or are not eligible for bariatric ... have a BMI over 40, are more than 100 pounds overweight, or have a ...
(Date:11/24/2015)... UT (PRWEB) , ... November 24, 2015 , ... It ... Magazine. For a business, it is critical that the first impression be positive and ... they are not likely to buy anything or want to return. They will also ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... gather to share their knowledge and experiences at a live taping of the ... Ruesch Center for the Cure of Gastrointestinal Cancers 2015 Symposium at Georgetown University ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Aided by ... today announced an innovative study designed to yield insights into how to detect and ... of biomarkers for pancreatic cancer from small, non-coding RNA molecules (ncRNA), genetic material that ...
(Date:11/24/2015)... ... November 24, 2015 , ... Sir Grout of Baltimore is ... certification. The award recognizes good companies for excellence in service and a commitment ... and hard surface restoration company earned this recognition after a thorough review by ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... November 24, 2015 F1000Workspace - ... - since it was launched just six months ago. ... and authoring platform for scientists - since it was launched ... have been loaded on to F1000Workspace - a ... since it was launched just six months ago. ...
(Date:11/24/2015)... YORK , Nov. 24, 2015 iRhythm Technologies, ... advancing cardiac care, today announced that it will participate in the ... Hotel in New York, NY . ... present on Tuesday December 1, 2015 at 8:50am ET. ... . --> . ...
(Date:11/24/2015)... uptake of recently approved and pipeline premium products for Type 1 Diabetes ... says GBI Research . --> The ... Mellitus (T1DM), will be a key driver of market growth to 2021, ... The uptake of recently approved and pipeline premium products for Type 1 ... 2021, says GBI Research . Type ...
Breaking Medicine Technology: